Home > Cardiology > AHA 2021 > Heart Failure > EMPULSE: Empagliflozin improves outcomes of acute heart failure

EMPULSE: Empagliflozin improves outcomes of acute heart failure

Presented By
Prof. Adriaan Voors, University of Groningen, the Netherlands

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AHA 2021
Trial
Phase 3, EMPULSE
Patients hospitalised for acute heart failure (HF) who were treated with empagliflozin showed significant clinical benefits over patients who were treated with placebo in the phase 3 EMPULSE trial. Empagliflozin therapy was associated with fewer deaths and HF events. Moreover, the agent showed a favourable safety profile in this vulnerable population [1]. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that has demonstrated efficacy in the treatment of patients with chronic HF [2,3]. The randomised, double-blind, placebo-controlled, phase 3 EMPULSE trial (NCT04157751) aimed to assess the efficacy and safety of empagliflozin in hospitalised patients with acute HF. De novo or decompensated hospital...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on